Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia
- PMID: 19652066
- DOI: 10.1200/JCO.2008.20.9692
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia
Abstract
Purpose: Reduced intensity conditioning regimen (RIC) is increasingly used in hematopoietic stem cell transplantation (HSCT). Unrelated donor (UD) transplants have more complications. We wanted to examine if RIC is a valid treatment option using UD in acute myeloblastic leukemia (AML).
Patients and methods: Between 1999 and 2005, 401 patients with AML were treated with RIC and 1,154 received myeloablative conditioning (MAC), using UD and reported to the European Group for Blood and Marrow Transplantation Registry. Patients < and > or = 50 years of age were analyzed separately.
Results: Patients receiving RIC were older, received transplants more recently, received peripheral blood stem cells more frequently, and were treated with total-body irradiation less often. In multivariable analysis, in patients younger than 50 years of age, nonrelapse mortality (NRM) was similar using RIC (hazard ratio [HR], 0.85; P = .41), relapse was increased (HR, 1.46; P = .02) and leukemia-free survival (LFS) was the same (HR, 0.88; P = .28), as compared with MAC. In patients > or = 50 years of age, NRM was decreased in the RIC group (HR, 0.64; P = .04), relapse probability was not significantly different (HR, 1.34; P = .16) and LFS was similar (HR, 1.04; P = .79) compared with MAC. CONCLUSION RIC-UD transplants are associated with higher relapse in AML patients younger than 50 years of age and decreased NRM in those > or = 50 years compared with MAC-UD. LFS was similar after both conditioning regimens, regardless of age. Therefore, RIC-UD extend the use of allotransplants for elderly patients and strategies that decrease relapse should be considered mainly in younger patients with AML.
Similar articles
-
Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.J Clin Oncol. 2006 Aug 20;24(24):3959-66. doi: 10.1200/JCO.2006.05.5855. Epub 2006 Jul 31. J Clin Oncol. 2006. PMID: 16880451
-
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.Biol Blood Marrow Transplant. 2008 Feb;14(2):181-6. doi: 10.1016/j.bbmt.2007.09.017. Epub 2007 Dec 31. Biol Blood Marrow Transplant. 2008. PMID: 18215778 Clinical Trial.
-
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.J Clin Oncol. 2010 Jan 20;28(3):405-11. doi: 10.1200/JCO.2009.21.8073. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008642
-
Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.Best Pract Res Clin Haematol. 2006;19(4):825-38. doi: 10.1016/j.beha.2006.06.007. Best Pract Res Clin Haematol. 2006. PMID: 16997186 Review.
-
Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Bone Marrow Transplant. 2008 Mar;41(5):425-37. doi: 10.1038/sj.bmt.1705973. Epub 2008 Jan 21. Bone Marrow Transplant. 2008. PMID: 18209727 Review.
Cited by
-
CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.Ann Hematol. 2024 Jan;103(1):241-249. doi: 10.1007/s00277-023-05502-0. Epub 2023 Oct 17. Ann Hematol. 2024. PMID: 37847380
-
Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.Transplant Cell Ther. 2023 Oct;29(10):611-618. doi: 10.1016/j.jtct.2023.07.015. Epub 2023 Jul 21. Transplant Cell Ther. 2023. PMID: 37481243
-
Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics.J Cancer Res Clin Oncol. 2023 Aug;149(10):7007-7015. doi: 10.1007/s00432-023-04657-7. Epub 2023 Mar 1. J Cancer Res Clin Oncol. 2023. PMID: 36856852 Free PMC article.
-
Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy.Front Oncol. 2022 Dec 2;12:1044539. doi: 10.3389/fonc.2022.1044539. eCollection 2022. Front Oncol. 2022. PMID: 36531001 Free PMC article.
-
Novel risk assessment for the intensity of conditioning regimen in older patients.Blood Adv. 2023 Sep 12;7(17):4738-4747. doi: 10.1182/bloodadvances.2022008706. Blood Adv. 2023. PMID: 36508283 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
